Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBS for Idiopathic Inflammatory Demyelinating Disease
NCT06474520Recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of calculus bovis sativus in idiopathic inflammatory demyelinating diseases of the central nervous system (IIDDs) (3 arms), sponsored by Tongji Hospital. Primary endpoints: Modified Rankin Scale at 12 weeks, Expanded Disability Status Scale at 12 weeks and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
calculus bovis sativus
03
Conditions
idiopathic inflammatory demyelinating diseases of the central nervous system (IIDDs)
Beyond the preview
Go deeper on NCT06474520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474520.